TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06449235
Drug: Thiazolidinediones
Normalized name: Thiazolidinediones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical Name: Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) Class: Thiazolidinediones (TZDs)~Mechanism of Action:~Activates peroxisome proliferator-activated receptor-gamma (PPAR-γ) in adipose tissue, muscle, and liver.~Increases insulin sensitivity in peripheral tissues. Enhances glucose uptake and utilization in muscle and adipose tissue. Reduces hepatic glucose production. Administration: Administered orally, typically once daily. Dosage may vary based on the specific medication and patient response.
Study: NCT06449235
Drug: Alpha-Glucosidase Inhibitor
Normalized name: Alpha-glucosidase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical Name: Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol) Class: Alpha-Glucosidase Inhibitors~Mechanism of Action:~Inhibits alpha-glucosidase enzymes in the small intestine. Delays the breakdown and absorption of complex carbohydrates. Reduces postprandial blood glucose levels. Administration: Administered orally, typically taken with the first bite of each main meal. Dosage may vary based on the specific medication and patient response.
Study: NCT06449235
Drug: Receptor Agonists (GLP1RA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical Name: GLP-1 Receptor Agonists (GLP1RA) (e.g., Exenatide, Liraglutide, Dulaglutide, Semaglutide) Class: Glucagon-Like Peptide-1 Receptor Agonists~Mechanism of Action:~Activates GLP-1 receptors. Enhances glucose-dependent insulin secretion. Suppresses glucagon secretion. Slows gastric emptying. Promotes satiety and reduces food intake. Improves β-cell function of the pancreas. Administration: Administered via subcutaneous injection, with frequency varying from twice daily to once weekly, depending on the specific medication.
Study: NCT05714345
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemotherapy for lymphodepletion
Study: NCT05935280
Drug: A967079
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific antagonist of the TRPA1 ion channel
Study: NCT05086276
Drug: FX-322
Normalized name: Prevail-FX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05086276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05946876
Drug: XH-S003 (A)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IP: XH-S003 IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral
Study: NCT00243763
Drug: TKI258
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06532617
Drug: Cadonilimab+S-1or Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible patients will receive Cadonilimab (6mg/k, iv, D1,Q3W)combined with S-1 (40-60mg po BID Q3W D1-14）or Capecitabine (1250mg/m2, po BID Q3W D1-14）until disease progression or unacceptable toxicity. Patients who had used S-1 in the first line should choose capecitabine; patients who had used capecitabine in the first line should choose S-1; otherwise decided by investigator's choice.
Study: NCT05308160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Study: NCT05180500
Drug: Q-Griffithsin
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q-Griffithsin is derived from Griffithsin (GRFT) which is a non-glycosylated protein consisting of 121 amino acids. Q-GRFT contains a single amino acid substitution, M78Q variant, resistant to oxidation yet maintains the parent molecule's pharmacological profile.
Study: NCT05180500
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A matched vehicle solution manufactured and dispensed in same applicators as the active comparator.
Study: NCT04708184
Drug: GLPG3970 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 for oral administration
Study: NCT04708184
Drug: GLPG3970 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3970 for oral administration
Study: NCT05586802
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This will be an active comparator for 26 weeks in Group 2 - Arm C
Study: NCT04767113
Drug: Heparin sodium
Normalized name: Heparin Sodium
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For infants without thrombosis at enrollment, heparin 1 U/kg/h/line for term infants was used and 0.5 U/kg/h/line for preterm infants. The speed of infusion was 0.5ml/h.~For infants with thrombosis at enrollment, heparin 10-15 U/kg/h for term infants was used with a target activated partial thromboplastin time 60-70s. Other interventions were at the clinical team's discretion under the local protocol.
Study: NCT04767113
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: For infants enrolled, normal saline was infused at the corresponding speed.
Study: NCT05145140
Drug: Standardized Western Medicine Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized Western Medicine Treatment includes hypoglycemic, debridement and anti infection treatments.
Study: NCT05145140
Drug: Tangningtongluo tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use tablet.
Study: NCT05145140
Drug: Tangningtongluo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangningtongluo(TNTL) , a traditional botanical ethnic medicine, composed of plantain, honeysuckle, agrimony, etc. It is famous for its effects of promoting blood circulation, dredging collaterals, reducing thirst and lowering glucose.The participants in this arm use cream.
Study: NCT04706559
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical corticosteroid, topical tacrolimus, an oral antihistamine and emollients as per atopic dermatitis treatment guidelines.
Study: NCT05460832
Drug: MBS2320 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05460832
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06388070
Drug: HUC3-053
Approvals — FDA: no, EMA: no, PMDA: no
Description: drops in each eye five to six times a day for 12 weeks
Study: NCT05138796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match TP-05 (lotilaner oral capsules)
Study: NCT06723197
Drug: vonoprazan+amoxicillin+tetracycline+bismuth
Normalized name: bismuth biskalcitrate / metronidazole / tetracycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combinations for quadruple regimens: vonoprazan+amoxicillin+tetracycline+bismuth
Study: NCT06704334
Drug: Ginkgo leaf dropping pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT06728657
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX: Capecitabine 1000 mg/m2 twice a day, days 1-14 and oxaliplatin 130 mg/m2, day 1, every 3 weeks
Study: NCT06727981
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: This intervention involves the administration of standard chemotherapy alone.
Study: NCT06012136
Drug: VH4004280
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4004280 will be administered.
Study: NCT06012136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT06012136
Drug: VH4011499
Approvals — FDA: no, EMA: no, PMDA: no
Description: VH4011499 will be administered.
Study: NCT04576663
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion simultaneous with subarachnoid block
Study: NCT06222268
Drug: Placebo only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered in the same way as active drugs through the vaporizer. Placebo cannabis material obtained through National Institute of Drug Abuse (NIDA) contains 0mg THC and 0mg CBD
Study: NCT06222268
Drug: THC:CBD 1:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis containing 2.5mg of THC and 2.5mg of CBD is delivered through a vaporizer.
Study: NCT06222268
Drug: THC:CBD 1:10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis containing 2.5mg THC and 25mg CBD is delivered through a vaporizer.
Study: NCT06055348
Drug: SC0191
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
Study: NCT06281561
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Female patients undergoing hysteroscopy receive nasal spray with normal saline before anesthesia
Study: NCT05297669
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours.
Study: NCT06394232
Drug: Eyecyte-RPE™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eyecyte-RPE™ is a suspension of hiPSCs (human induced Pluripotent Stem Cells) derived Retinal Pigment Epithelial Cells
Study: NCT01938196
Drug: KWA-0711
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01938196
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00063427
Drug: MAC-321
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04963764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive oral placebo for a standard course (10 days)
Study: NCT06373523
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo pills will be manufactured to be identical in appearance to the study drug(Dapaglifozin 10 mg tablet).
Study: NCT06373523
Drug: Levothyroxine Replacement daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine Replacement daily for 28 weeka
Study: NCT05271552
Drug: BXCL501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Film
Study: NCT05271552
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Placebo Film
Study: NCT04811131
Drug: ARQ-252 cream 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-252 cream 0.3%
Study: NCT04811131
Drug: ARQ-252 Vehicle cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-252 Vehicle cream
Study: NCT05617430
Drug: HAIC
Normalized name: Hepatic Arterial Infusion Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin: 85mg/m2 , Day 1 Leucovorin: 200mg/m2, Day 1 Fluorouracil: 400mg/m2, Day1 and 2400mg/m2 continuous arterial perfusion for 46h.~Q3W
Study: NCT03678428
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Leucovorin 200mg/m2 IV on Day 1 and 15.
Study: NCT00992862
Drug: Univasc® 15mg Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05120076
Drug: NaCl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: s. arm/group description
Study: NCT05832697
Drug: Ursodeoxycholic Acid 250 Mg Oral Tablet
Normalized name: Ursodeoxycholic acid 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Ursodeoxycholic Acid 250 Mg Oral Tablet or Ursodeoxycholic Acid 100 Mg Oral Tablet
Study: NCT04726553
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care treatments for Systemic Lupus Erythematosus
Study: NCT05915871
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration
Study: NCT05980481
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2 per os Q3W
Study: NCT05468671
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil is an esterase-metabolized opioid
Study: NCT05032144
Drug: STSA-1002 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05032144
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT05256823
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Celecoxib twice daily for 48 weeks.
Study: NCT05256823
Drug: nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue ongoing nucleos(t)ide analogue (Entecavir or Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide Fumarate) therapy for 48 weeks
Study: NCT06727617
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin: Administered by intravenous infusion during concurrent chemoradiotherapy at a dose of 30-40 mg/m² once weekly for only 5-6 treatment cycles; during sequential chemoradiotherapy, administered at 60-75 mg/m² on the first and second days of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.~Paclitaxel: Nab-paclitaxel administered by intravenous infusion at a dose of 135-175 mg/m² on the first day of each cycle, once every 3 weeks (21 days) for only 4 treatment cycles.
Study: NCT04862260
Drug: Cholesterol metabolism disruption
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol metabolism disruption using a combination of atorvastatin, ezetimibe and evolocumab in metastatic pancreatic adenocarcinomas
Study: NCT05814757
Drug: Collagen Punctal Plug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen Punctal Plug 0.2mm (Full Insertion)
Study: NCT06213259
Drug: KD6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological: KD6005, SQ
Study: NCT06213259
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, SQ
Study: NCT04818944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be dosed for 24 hours post MT via continuous IV
Study: NCT05269511
Drug: Chinese herbal medicine is in the form of granules (9 g/sachet), which is comprised of ten medicinal herbs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration, twice per day.
Study: NCT05581056
Drug: CFTR modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Introduction of CFTR modulators by pneumologists for pneumologic issues
Study: NCT01354184
Drug: CRD007
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06465472
Drug: Placebo Oral Capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules will be administered for the first 6 months. Then patients will switch to stiripentol over the 6- to 12-month period.
Study: NCT01354184
Drug: CRD007 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05700734
Drug: MK-8510
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of MK-8510 administered as a tablet at a dose up to 2200 mg.
Study: NCT05633433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04797650
Drug: CTP-543 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as tablets.
Study: NCT05175781
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT05412004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04644029
Drug: Placebo to FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg tablet administered once daily during Part 1.
Study: NCT04644029
Drug: FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 200 mg emtricitabine and 245 mg of tenofovir disoproxil (equivalent to 300 mg tenofovir disoproxil fumarate or 201.22 mg tenofovir disproxil phosphate), administered orally once daily in Parts 1, 2, and 3.
Study: NCT04644029
Drug: Placebo to ISL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg tablet administered orally once monthly in Part 1.
Study: NCT04802616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched tablets without any active substance.
Study: NCT04120636
Drug: Episcleral Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained Release Transscleral Celecoxib
Study: NCT06147908
Drug: DW5221
Approvals — FDA: no, EMA: no, PMDA: no
Description: megestrol acetate
Study: NCT06147908
Drug: DW5221-R
Normalized name: R
Approvals — FDA: no, EMA: no, PMDA: no
Description: megestrol acetate
Study: NCT05156684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two placebo tablets daily
Study: NCT05156684
Drug: zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive one zinc sulfate tablet daily
Study: NCT05156684
Drug: zinc + pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infertile men referred to the infertility treatment center who, have had at least one year of unprotected intercourse, Natural fertility has not happened in their spouse. These men will all be married These men will be between the ages of 20 and 50. According to WHO criteria, Sperm parameters abnormalities should be observed in at least two spermogram within 2 weeks. Candidates receive two pentoxifylline tablets+ one zinc tablet daily
Study: NCT05648799
Drug: GP30341 capsules 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: orall take of capsules twice a day
Study: NCT05648799
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medicines for treatment of a new coronavirus infection 2019 (COVID-19).
Study: NCT05190627
Drug: Placebo 10mg/day added to rapamycin for 12 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in the same type of capsule than the experimental drug
Study: NCT06165432
Drug: Topical Benzocaine
Normalized name: benzocaine Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzocaine topical anesthetic gel will be used a pre-injection anesthetic on one half of the palate before giving greater palatine nerve block
Study: NCT00057174
Drug: Disease management of gastroesophageal reflux disease
Normalized name: INVESTIGATIONAL DRUGS FOR GASTROESOPHAGEAL REFLUX DISEASE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04282174
Drug: Hyperfractionated Total Body Irradiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfractionated Total Body Irradiation is administered at a dose rate of \< 20 cGy/minute. Doses of 125 cGy/fraction are administered at a minimum interval of 4 hours between fractions, three times/day for a total of 11 or 12 doses (1375 or 1500 cGy) over 4 days (Day -9, -8, -7 and -6).
Study: NCT04282174
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide: 60 mg/kg/day I V over approximately 30 min daily x 2 days (d -3 and -2). Cyclophosphamide dosing will be adjusted if patient is \> 125% of ideal body w eight and will be calculated based on adjusted ideal body weight, as per MCI standard of care guidelines.
Study: NCT04428372
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 'placebo' arm
Study: NCT06258850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Study: NCT05478239
Drug: ArtemiCoffee
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cups of Artemisia annua (Aa) coffee per day (1350mg) for 24 weeks.
Study: NCT05892510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intra-arterial bolus of 0.9% Sodium Chloride solution
Study: NCT05401565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05603013
Drug: PD-1/PD-L1 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitor subcutaneous injection or intravenous injection
Study: NCT06452498
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule filled with cellulose.
Study: NCT05299697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin) as well as calorie restrict diet and increased physical activity for 24 weeks.
Study: NCT04879017
Drug: FHD-286
Approvals — FDA: no, EMA: no, PMDA: no
Description: FHD-286 as a single agent
Study: NCT06267092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive subcutaneous (s.c.) injections of placebo matched to Cagrilintide and Semaglutide.
Study: NCT06303505
Drug: TUB-040
Approvals — FDA: no, EMA: no, PMDA: no
Description: A complete treatment cycle is defined as 21 calendar days. TUB-040 will be administered as an intravenous (IV) solution on day 1 of each treatment cycle